Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks

Executive Summary

Limited population approval pathway in 21st Century Cures law may not help Cempra overcome US agency's request for new 9,000-patient safety study of the macrolide antibiotic.


Related Content

Cempra Gets Easier Path To CRL Response, But Who Will Fund The Study?
Antibiotic Pipeline Profile: Balancing Broad Spectrum And Limited Use
Antibiotics Pipeline Is Lively, But Sponsors Are Fragile
Antibiotic Development: Limited Population Pathway In US Removes Barrier
The First LPAD? Cempra May Try New Pathway For MRSA Antibiotic, Could Retrofit Solithromycin
Rx For Industry: Key Provisions Of The 21st Century Cures Act
The Evolution Of 21st Century Cures Legislation
Cempra’s Antibiotic Likely Needs Bigger Trial – But Might Be Able To Do It In Phase IV
Cempra To Defend CABP Antibiotic's Safety At US FDA Advisory Panel
FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts